Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.

Here's Why Novartis (NVS) Fell More Than Broader Market

AstraZeneca

L'Oreal SA

Nestle SA

Roche Holding AG

SAP SE

ASML Hld

GlaxoSmithKline

Novo Nordisk

Sanofi

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.

UK's MHRA revokes authorisation for Novartis' sickle cell drug

Amgen

Biogen

Bristol-Myers

Gilead Sciences

Last October, life sciences giant Thermo Fisher Scientific (NYSE: TMO ) inadvertently laid out the case for contrarian biotech stocks. According to Reuters, the company revealed that a slump in demand from the biotech sector for its services could extend into 2024.

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

Morphosys AG - ADR

Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer treatments.

Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline

Novartis AG has announced the acquisition of Germany-based cancer drug maker MorphoSys AG through a €2.7 billion deal. Unveiling the takeover on Monday, Novartis said the move would expand its oncology pipeline, relating to cancer treatments, alongside widening its footprint in haematology - blood disease studies.

Novartis to buy cancer drug maker MorphoSys for €2.7 billion

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

Novartis acquires cancer drug developer MorphoSys for $2.9 bln

Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65% of outstanding shares tendered in the takeover offer and regulatory approvals, further expands and complements Novartis pipeline in oncology, one of its priority therapeutic areas, while also enhancing Novartis global footprint in hematology.

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG , a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said on Monday.

Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will be distributed by Valeo until late this year, rather than for an initially agreed seven-year term, following Bausch and Lomb's acquisition of the brand from Novartis in September.

Valeo Pharma amends Novartis eye treatment distribution agreement

LVMH Moet Hennessy Louis Vuitton

Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.

It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.

AbbVie

Pfizer

AbbVie is a Dividend King with plenty of growth potential left. Novartis offers investors a high dividend yield and strong prospects.

3 Fabulous Dividend Stocks to Buy in February

Eli Lilly

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

4 Large Drug Stocks Trying to Survive the Industry Challenges

Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell short of analyst's expectations, and the company also ended a study on an experimental blood cancer treatment. American Depositary Receipts (ADRs) of the Swiss drugmaker were down more than 3% in afternoon trading in New York.

Novartis Stock Slumps After Drugmaker's Earnings, Guidance Fall Short of Expectations

Novartis AG (NVS) Q4 2023 Earnings Call Transcript

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Novartis (NVS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Novartis shares dropped around 5% after it reported fourth-quarter earnings and sales that missed consensus expectations and issued guidance that analysts said fell short of hopes.

Novartis Earnings, Outlook Fall Short

Switzerland's Novartis on Wednesday updated its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.

Novartis eyes 5% annual sales growth through 2028

Ad hoc announcement pursuant to Art. 53 LR Full year (continuing operations 2 ) Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD) Sales growth was mainly driven by continued strong performance from Entresto (+31% cc), Kesimpta (+99% cc), Kisqali (+75% cc), Pluvicto (+261% cc) and Scemblix (+179% cc) Operating income increased +39% (cc, +23% USD).

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

News for Novartis Stock (NVS)